University College London Institute of Neurology, Queen Square, London WC1N 3BG, England.
Neurology. 2010 Mar 9;74(10):846-50. doi: 10.1212/WNL.0b013e3181d5276d.
The clinical phenotype of DYT6 consists mainly of primary craniocervical dystonia. Recently, the THAP1 gene was identified as the cause of DYT6, where a total of 13 mutations have been identified in Amish-Mennonite and European families.
We sequenced the THAP1 gene in a series of 362 British, genetically undetermined, primary dystonia patients (78 with focal, 186 with segmental, and 98 with generalized dystonia) and in 28 dystonia-manifesting DYT1 patients and 176 normal control individuals.
Nine coding mutations were identified in the THAP1 gene. Two were small deletions, 2 were nonsense, and 5 were missense. Eight mutations were heterozygous, and 1 was homozygous. The main clinical presentation of cases with THAP1 mutations was early-onset (<30 years) dystonia in the craniocervical region or the limbs (8 of 9 patients). There was phenotypic variability with laryngeal or oromandibular dystonia present in 3 cases. Four of 9 THAP1 cases developed generalized dystonia.
The number of THAP1 mutations has been significantly expanded, indicating an uncommon but important cause of dystonia. Coding mutations account for 9 of 362 dystonia cases, indicating a mutation frequency of 2.5% of dystonia cases in the population that we have screened. The majority of cases reported here with THAP1 mutations had craniocervical- or limb-onset segmental dystonia, but we also identified 1 homozygous THAP1 mutation, associated initially with writer's dystonia and then developing segmental dystonia. Three of our patients had a nonsense or frameshift THAP1 mutation and the clinical features of laryngeal or oromandibular dystonia. These data suggest that early-onset dystonia that includes the involvement of the larynx or face is frequently associated with THAP1 mutations.
DYT6 的临床表型主要为原发性颅颈肌张力障碍。最近,THAP1 基因被确定为 DYT6 的致病基因,在阿米什-门诺派和欧洲家族中已发现总共 13 种突变。
我们对 362 名英国、遗传未定的原发性肌张力障碍患者(78 名局灶性、186 名节段性和 98 名全身性肌张力障碍患者)和 28 名 DYT1 显性肌张力障碍患者以及 176 名正常对照个体进行了 THAP1 基因测序。
在 THAP1 基因中发现了 9 个编码突变。其中 2 个是小缺失,2 个是无义突变,5 个是错义突变。8 个突变是杂合的,1 个是纯合的。THAP1 突变病例的主要临床表现为早发性(<30 岁)颅颈区或四肢肌张力障碍(9 例患者中有 8 例)。有 3 例存在喉或口面肌张力障碍的表型变异性。9 例 THAP1 病例中有 4 例发展为全身性肌张力障碍。
THAP1 突变的数量显著增加,表明这是一种不常见但重要的肌张力障碍病因。编码突变占 362 例肌张力障碍病例的 9 例,表明我们筛选的人群中肌张力障碍病例的突变频率为 2.5%。这里报告的大多数 THAP1 突变病例为颅颈或肢体起病的节段性肌张力障碍,但我们也发现了 1 例纯合 THAP1 突变,最初表现为书写痉挛,然后发展为节段性肌张力障碍。我们的 3 名患者存在无义或移码 THAP1 突变,表现为喉或口面肌张力障碍的临床特征。这些数据表明,包括喉或面部受累在内的早发性肌张力障碍常与 THAP1 突变相关。